An investigation is underway after two fraternities at the University of Central Florida, Sigma Chi and Delta Upsilon, were ...

Ongoing Phase 1 and Phase 2 clinical programs continue to exhibit long-term durable remissions in hard-to-treat cancers, ...

IN8bio, Inc., a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies, has reported strong progress in its Phase 1 and Phase 2 clinical programs, showing ...

The University of Central Florida’s police department is investigating two fraternities following “multiple reports” of hazing activities “that were both dangerous and degrading,” a university ...

Adicet Bio specializes in the development of off-the-shelf gamma-delta T cell therapies for the treatment of cancer and autoimmune diseases. The company's innovative approach leverages the unique ...

IN8bio (INAB) unveiled INB-600, its next generation gammadelta T cell-based TCE platform. It is designed to address one of the biggest ...

(RTTNews) - IN8bio, Inc. (INAB) announced the launch of its next-generation Gamma-Delta T-cell engager or TCE platform INB-600, designed to overcome the limitations of existing Gamma-Delta TCE ...

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies, today unveiled INB ...

Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biopharmaceutical company with a market capitalization of $65.5 million, focuses on developing engineered gamma-delta T cell therapies. The company ...

Proprietary platform represents the first known approach capable of sustained gamma-delta T cell expansion, eliminating target cells with robust potencyINB-619, a next generation gamma-delta TCE targe ...

Adicet Bio, Inc. (NASDAQ:ACET), a clinical-stage biopharmaceutical company with a market capitalization of $65.5 million, focuses on developing engineered gamma-delta T cell therapies. The company ...